"The multidisciplinary team in GENEGUT will pioneer the development of the next generation of therapeutics for the treatment of IBD"
Prof. Caitriona O’Driscoll
Project Coordinator

GENEGUT brings together 9 partners from 8 European countries covering the lifecycle from bench to bedside.

Through a patient-centred approach and grown out of the recent Cost Action UNGAP (CA16205), GENEGUT brings together a patient association with renowned researchers, expert clinical scientists, SMEs and large pharma companies with expertise and patented technologies in global proteomics, nanotechnologies, cyclodextrin synthesis, multicellular models, drug delivery systems and production as well as innovation management, stakeholder involvement and science communication.

GENEGUT benefits from the special partnership between the University College Cork’s School of Pharmacy, represented by GENEGUT project coordinator Prof. Caitriona O’Driscoll, and the APC Microbiome Ireland SF1 Research Centre under principal investigator and Consultant Gastroenterologist Prof. Subrata Ghosh. Both research groups share a long history of fruitful collaboration, and a track record of translational research in the field of drug delivery and the treatment of inflammatory bowel disease. This partnership unites pre-clinical and clinical skills and will enable the UCC team to join forces for the development of an RNA-based therapy for ileal CD.

University College Cork (UCC)

School of Pharmacy
APC Microbiome

  • Project coordination and management
  • Synthesis, formulation and characterisation of therapeutic RNA-based nanoparticles
  • Cellular specificity and mechanism
  • Proof of efficiacy under diseased conditions
Prof. Caitriona O'Driscoll
Project Coordinator
Prof. Brendan Griffin
Prof. Subrata Ghosh
Dr. Piotr Kowalski
Dr. Silvia Melgar
Dr. Joseph O'Shea
  • Dr. Ken Nally 
  • Dr. Patrick O’Dwyer

Bangor University (BU)

School of Medical Health Sciences

  • Early Health Technology Assessment and Regulatory Preparedness
Prof. Dyfrig Hughes
Su Hang

Institute for Research and Innovation in Health (i3S)

i3s Porto

  • Proof of efficiacy under diseased conditions
    Efficiacy of targets on optimised 3D multicellular model of ileal CD
Prof. Bruno Sarmento
Dr. Catarina Pereira

Uppsala University (UU)

Department of Pharmacy

  • Cellular specificity and mechanism
    Establish relevant healthy and diseased intestinal cell models
    Kinetics and mechanisms of RNA nanoparticle uptake
    Intracellular localization and endosomal escape
Prof. Per Artursson
Dr. Madlen Hubert



  • Synthesis, formulation and characterisation of therapeutic RNA-based nanoparticles
    Chemistry of the biomaterials
    Formulation and characterisation of NPs containing RNA
Dr. Milo Malanga
Tamas Vagardi
Dr. Kristóf Felegyi
Daniel Bisericaru
Mihály Bálint
Tamas Sohajda

Janssen Pharmaceutica NV

Discovery, Product Development & Supply

Establishing simulated patient model of CD through in silico PBBM

Dr. Jens Ceulemans
Dr. Abhishek Singh
Dr. Sumit Arora
  • Dr. Giustino Di Pretoro

Lonza Capsules & Health Ingredients - Capsugel SAS

Lonza Applications Lab

  • Formulation development for regional specificity
    Drug delivery system targeted at ileocaecal junction
    In vitro characterisation – stability and site-specific releaselonza capsue
Dr. Vincent Jannin
Dr. Camille Dumont
Dr. Pierre Verlhac
  • Dr. Remi Fournier
  • Dr. Ljilijana Palangetic
  • Dr. Stephanie Laurichesse-Ohnimus 

European Federation of Crohn's and Ulcerative Colitis Associations


  • Communication, dissemination and exploitation of results
    Disseminate scientific and technological results
Ms. Isabella Haaf
  • Mrs. Luisa Avedano 
  • Mr. Salvo Leone
  • Ms. Maria Stellla de Rocchis

accelopment Schweiz AG


  • Communication, dissemination and exploitation of results
  • Project coordination and management
Dr. Jeanette Müller
Dr. Emily Rose Ciscato
Ms. Jamuna Siehler